THE WOODLANDS, Texas--(BUSINESS WIRE)--MolecularHealth announced today that it will attend the Best of ASCO® symposium in Hollywood, Florida this week as a silver sponsor. The symposium will be held on August 29-30, 2014 and is presented by Memorial Cancer Institute.
The Best of ASCO symposium program is designed to educate physicians and healthcare professionals on the latest advances in clinical and translational cancer research. An expert panel selects abstracts to be presented from the 2014 ASCO Annual Meeting that showcase the latest scientific findings in hematology, oncology, surgical oncology and radiation oncology.
As a sponsor and exhibitor, MolecularHealth will showcase its cancer treatment decision support offering, TreatmentMAP™, which commercially launched in the United States and Europe earlier this year. Using a proprietary automated analytics platform, TreatmentMAP leverages the results of next-generation sequencing genetic tests performed in MolecularHealth’s CLIA-certified Texas-based laboratory to identify the optimal, safest treatment options for each individual patient.
Westin Diplomat Resort & Spa – Beach Location
3555 South Ocean Drive
Hollywood, FL 33019
MolecularHealth is a leading biomedical company that is transforming molecular data into clinically actionable information to inform the most efficient and safest cancer treatment options for each individual cancer patient.
In the U.S., TreatmentMAPTM is a laboratory developed test (LDT) performed at MolecularHealth’s CLIA-certified laboratory. In Europe, TreatmentMAP is the first registered medical device of its kind for personalized cancer medicine and offered through a network of certified physicians. MolecularHealth GmbH is certified according to DIN EN ISO 13485.
MolecularHealth, comprised of a multidisciplinary team of oncologists, scientists, businesspeople, and IT experts with long-standing expertise in their fields, works in partnership with some of the world’s leading healthcare, information technology and NGS companies, including the U.S. Food and Drug Administration (FDA), University of Texas MD Anderson Cancer Center, SAP AG and GATC Biotech.
Located in the centers of cancer research in Europe and U.S., the company is headquartered in Heidelberg, Germany, and its U.S. headquarters, including a CLIA-certified NGS lab, is located in The Woodlands, Texas. The company also has offices in Boston, Mass.